Behzad Aghazadeh: Stock Portfolio, Performance and Latest Trades
Avoro Capital Advisors
13F portfolio value
$11.1B
26 holdings at Q2 2026
Get an email when Behzad Aghazadeh files a new 13F report
Free, no account needed. Unsubscribe with one click.
Behzad Aghazadeh's portfolio
As of Q2 2026, filed August 14, 2026 · prices as of October 8, 2026
| Company | Share of portfolio | Average buy price | Return | Current price | Last quarter |
|---|---|---|---|---|---|
| 13.5% | $230.66 | +131% | $532.78 | Added +5.6% | |
| 12.2% | $233.60 | −4.7% | $222.69 | New | |
| 9.64% | $98.30 | +233% | $327.30 | No change | |
| 8.84% | $164.70 | +190% | $476.91 | Added +0.8% | |
Argenx SE - ADRARGX | 8.33% | $202.39 | +304% | $818.63 | No change |
| 8.31% | $31.88 | +90.5% | $60.74 | Added +6.1% | |
| 7.70% | $40.15 | +172% | $109.30 | No change | |
| 3.86% | $68.20 | +176% | $188.12 | Reduced −2.0% | |
| 3.82% | $66.30 | −6.5% | $62.01 | Added +50% | |
Celcuity Inc.CELC | 3.19% | $84.53 | −19.7% | $67.87 | Added +0.7% |
| 3.16% | $30.52 | −15.9% | $25.67 | No change | |
| 3.13% | $21.15 | +70.9% | $36.16 | No change | |
| 3.04% | $19.33 | +76.9% | $34.18 | Added +44% | |
Uniqure NVQURE | 2.78% | $26.37 | −14.5% | $22.54 | Added +13% |
| 2.21% | $36.12 | −17.7% | $29.73 | Reduced −2.8% | |
| 1.46% | $2.62 | +69.3% | $4.43 | Added +10% | |
| 1.11% | $8.69 | −13.5% | $7.51 | Added +1.8% | |
Damora Therapeutics Inc.36322Q206 | 0.88% | $25.90 | — | — | No change |
| 0.63% | $27.59 | +12.0% | $30.89 | New | |
GH Research PLCGHRS | 0.43% | $13.62 | +50.1% | $20.45 | No change |
| 0.41% | $22.90 | −19.9% | $18.34 | Added +67% | |
Septerna Inc.SEPN | 0.40% | $20.05 | +84.0% | $36.90 | No change |
| 0.39% | $15.70 | −14.5% | $13.43 | Added +65% | |
| 0.32% | $23.13 | +10.7% | $25.61 | New | |
| 0.12% | $24.27 | −85.7% | $3.47 | No change | |
| 0.06% | $9.13 | −64.8% | $3.21 | Reduced −21% |
Behzad Aghazadeh's options
As of Q2 2026. Value = shares the options cover.
| Company | Type | Value of shares covered | Last quarter |
|---|---|---|---|
Celcuity Inc.CELC | Call · bet on a rise | — | Sold out |
| Call · bet on a rise | — | Sold out |
Behzad Aghazadeh's buys and sells
| Company | Action | Shares change | Value now |
|---|---|---|---|
Blueprint Medicines Corp.09627Y109 | Reduced −90% | −3,475,000 | $48.1M |
Akero Therapeutics Inc.00973Y108 | New | +3,500,000 | $186.8M |
| Sold out | −2,674,835 | — | |
| Reduced −11% | −305,000 | $681M | |
| Reduced −2.6% | −71,000 | $365.6M | |
| Added +1.5% | +95,555 | $286.1M | |
| Reduced −7.3% | −147,222 | $567.5M | |
| Added +50% | +1,379,900 | $195.9M | |
Argenx SE - ADRARGX | Reduced −4.9% | −60,177 | $647.7M |
Intra-Cellular Therapies Inc.46116X101 | Sold out | −625,000 | — |
Amicus Therapeutics Inc.03152W109 | Reduced −12% | −2,500,000 | $103.1M |
Ascendis Pharma A/S04351P101 | Reduced −4.6% | −238,000 | $859.5M |
Merus NVN5749R100 | Added +5.2% | +155,555 | $166M |
Vaxcyte Inc.PCVX | Sold out | −1,000,000 | — |
Uniqure NVQURE | Added +67% | +1,450,000 | $50.5M |
| Reduced −4.6% | −511,111 | $167.5M | |
| Reduced −48% | −4,200,000 | $40.3M | |
Avidity Biosciences Inc.05370A108 | Reduced −7.5% | −575,000 | $200.2M |
| Reduced −6.0% | −341,666 | $169M | |
| Added +8.5% | +1,700,001 | $50.1M | |
Mannkind Corp.MNKD | Reduced −33% | −2,900,000 | $21.9M |
89bio Inc.282559103 | Added +6.3% | +400,000 | $66.3M |
| Reduced −60% | −500,000 | $12M | |
| Sold out | −9,910,642 | — | |
| Added +10% | +598,100 | $148.4M | |
| Reduced −8.2% | −660,000 | $68.7M | |
Soleno Therapeutics Inc.834203309 | Reduced −19% | −475,000 | $171.7M |
Centessa Pharmaceuticals-Adr152309100 | Added +23% | +950,000 | $65.7M |
Septerna Inc.SEPN | Reduced −7.5% | −100,000 | $13.1M |
| Reduced −20% | −920,548 | $16.8M | |
| Added +5.4% | +130,555 | $40.9M | |
Alkermes PLCALKS | Added +18% | +450,000 | $83M |
Behzad Aghazadeh's portfolio by sector
Share of the stock portfolio at Q2 2026.
| Sector | Share |
|---|---|
| Health Care | 99% |
| Other | 0.9% |
Portfolio performance: Behzad Aghazadeh vs. benchmarks
Your result if you had bought each reported portfolio on the day it was made public and held it until the next report, against the S&P 500 and Nasdaq-100.
- You, copying after each 13F filing – estimated value
- S&P 500
- Nasdaq-100
| Total return | Per year | |
|---|---|---|
| You, copying after each 13F filing – estimated value | +68.1% | +10.9% |
| S&P 500 | +89.0% | +13.6% |
| Nasdaq-100 | +113.3% | +16.4% |
Prices were available for 43% of the portfolio value on average; the rest is left out of the return.
Behzad Aghazadeh's most traded stocks
Quarters with a buy or a sell, all reports since Q4 2014.
| Company | Quarters bought | Quarters sold |
|---|---|---|
| 28 | 9 | |
| 22 | 15 | |
| 18 | 16 | |
| 21 | 11 | |
| 22 | 7 | |
| 17 | 11 | |
Argenx SE - ADRARGX | 16 | 10 |
| 16 | 9 | |
| 13 | 11 | |
| 9 | 11 | |
| 9 | 9 | |
| 13 | 4 | |
| 14 | 3 | |
Uniqure NVQURE | 10 | 6 |
| 13 | 3 |